ReviewTransplant international : official journal of the European Society for Organ Transplantation2013
Proteomics and metabolomics in renal transplantation-quo vadis?
Review in Transplant international : official journal of the European Society for Organ Transplantation, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- An Exosomal mRNA Urine Test for Detection and Risk Stratification of Human Kidney Transplant Rejection.Kidney international reports · 2025Article
- Proteomic analysis investigating kidney transplantation outcomes- a scoping review.BMC nephrology · 2023Article
- Molecular Markers of Kidney Transplantation Outcome: Current Omics Tools and Future Developments.International journal of molecular sciences · 2022Review
- Serum metabolomics approach to monitor the changes in metabolite profiles following renal transplantation.Scientific reports · 2020Article
- Targeted Urine Metabolomics for Monitoring Renal Allograft Injury and Immunosuppression in Pediatric Patients.Journal of clinical medicine · 2020Article
- Kidney transplant monitoring by urinary flow cytometry: Biomarker combination of T cells, renal tubular epithelial cells, and podocalyxin-positive cells detects rejection.Scientific reports · 2020Article
- Advances in Detection of Kidney Transplant Injury.Molecular diagnosis & therapy · 2019Review
- Role of biobanks in transplantation.Annals of medicine and surgery (2012) · 2018Review
- Metabolomics identifies metabolite biomarkers associated with acute rejection after heart transplantation in rats.Scientific reports · 2017Article
- Biomarkers in renal transplantation: An updated review.World journal of transplantation · 2017Review
- Non-invasive approaches in the diagnosis of acute rejection in kidney transplant recipients, part II: omics analyses of urine and blood samples.Clinical kidney journal · 2017Review
- Changing Paradigms in the Management of Rejection in Kidney Transplantation: Evolving From Protocol-Based Care to the Era of P4 Medicine.Canadian journal of kidney health and disease · 2017Article
- The Use of Genomics and Pathway Analysis in Our Understanding and Prediction of Clinical Renal Transplant Injury.Transplantation · 2016Review
- Biomarkers in Transplantation--Proteomics and Metabolomics.Therapeutic drug monitoring · 2016Review
- Urine Metabolite Profiles Predictive of Human Kidney Allograft Status.Journal of the American Society of Nephrology : JASN · 2016Article
- Article
- Epigenetics in Kidney Transplantation: Current Evidence, Predictions, and Future Research Directions.Transplantation · 2016Review
- Metabolomics and renal disease.Current opinion in nephrology and hypertension · 2015 · on this mapReview
- A high-performance liquid chromatography-tandem mass spectrometry-based targeted metabolomics kidney dysfunction marker panel in human urine.Clinica chimica acta; international journal of clinical chemistry · 2015Article
- Insights from computational modeling in inflammation and acute rejection in limb transplantation.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The improvement of long-term transplant organ and patient survival remains a critical challenge following kidney transplantation. Proteomics and biochemical profiling (metabolomics) may allow for the detection of early changes in cell signal transduction regulation and biochemistry with high sensitivity and specificity. Hence, these analytical strategies hold the promise to detect and monitor disease processes and drug effects before histopathological and pathophysiological changes occur. In addition, they will identify enriched populations and enable individualized drug therapy. However, proteomics and metabolomics have not yet lived up to such high expectations. Renal transplant patients are highly complex, making it difficult to establish cause-effect relationships between surrogate markers and disease processes. Appropriate study design, adequate sample handling, storage and processing, quality and reproducibility of bioanalytical multi-analyte assays, data analysis and interpretation, mechanistic verification, and clinical qualification (=establishment of sensitivity and specificity in adequately powered prospective clinical trials) are important factors for the success of molecular marker discovery and development in renal transplantation. However, a newly developed and appropriately qualified molecular marker can only be successful if it is realistic that it can be implemented in a clinical setting. The development of combinatorial markers with supporting software tools is an attractive goal.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.